GLI Celebrates with PBC Patient Community upon U.S. FDA’s Approval of Second-Line Treatment
Global Liver Institute applauds U.S. Representative Nydia Velázquez (D-NY) for reintroducing this vital legislation to improve the lives of all people impacted by liver disease. GLI was proud to collaborate in the development of The Liver Illness, Visibility, Education and Research Act (LIVER Act), first introduced in 2018.
Access to care takes center stage for liver disease patients – Liver Health Policy Update
GLI responds to VA efforts to deny or delay access to NASH/MASH treatment while proactively pushing for Congress to advance policies that support access to comprehensive care for liver disease patients.
The Quiet Threat of Fatty Liver in Lean Individuals
Nonalcoholic fatty liver disease (NAFLD or more recently metabolic dysfunction-associated steatotic liver disease, MASLD) has long been associated with obesity, but researchers are beginning to look into the trend that a sizable portion of those with the disease actually has a “normal” or lean weight.
Nourishing Insights into Pediatric Fatty Liver Disease
Over the past decade, the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD, previously known as nonalcoholic fatty liver disease/NAFLD) in children has seen a concerning rise.
Biomarker identified for infants with alpha-1 antitrypsin deficiency – Pediatric & Rare Liver Diseases News
The GLI Pediatric and Rare Liver Diseases team was thrilled to attend the BARE Symposium on May 10-11, 2024.